SPARC inhibitors belong to a distinct chemical class of compounds that are meticulously designed to modulate the activity of the SPARC protein. SPARC, also known as Secreted Protein Acidic and Rich in Cysteine, is an important extracellular matrix-associated protein that plays diverse roles in cell-matrix interactions, tissue remodeling, and cell signaling. These inhibitors are carefully developed molecules engineered to interact with the SPARC protein, influencing its normal functions. Through these interactions, they may affect various cellular processes associated with extracellular matrix regulation and cell behavior, without directly altering its binding to other molecules or its downstream effects.
The design of SPARC inhibitors is based on a comprehensive understanding of the structural and functional characteristics of the SPARC protein. Typically developed using advanced chemical synthesis methods and informed by insights from structural biology, these inhibitors are characterized by their ability to selectively bind to SPARC. This selectivity allows for precise modulation of cellular pathways that rely on SPARC's involvement. Researchers and scientists engaged in uncovering the complexities of tissue microenvironment, cell-matrix interactions, and tissue remodeling processes often employ SPARC inhibitors as valuable tools. Through systematic experimentation, they can explore how the inhibition of SPARC influences cellular processes, thereby contributing to a deeper understanding of its role in various physiological and cellular contexts. The development and utilization of SPARC inhibitors contribute to advancing our knowledge of the intricate interplay between cellular components and extracellular matrix dynamics, providing insights into the fundamental molecular mechanisms that govern tissue structure and adaptation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bosentan | 147536-97-8 | sc-210957 | 10 mg | $195.00 | 3 | |
This dual endothelin receptor antagonist indirectly affects SPARC expression by influencing endothelin signaling, which is linked to SPARC modulation. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
An integrin inhibitor, it indirectly impacts SPARC's functions by affecting integrin-mediated cell adhesion and signaling. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Inhibits the Hedgehog signaling pathway, which can cross-talk with SPARC-related pathways, potentially affecting SPARC-mediated processes. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Demonstrates effects on SPARC expression in certain contexts, potentially modulating its interactions with the extracellular matrix. | ||||||
Caffeic acid phenethyl ester | 104594-70-9 | sc-200800 sc-200800A sc-200800B | 20 mg 100 mg 1 g | $71.00 $296.00 $612.00 | 19 | |
Exhibits anti-inflammatory properties and may influence SPARC expression as part of its broader effects. | ||||||
Tetrandrine | 518-34-3 | sc-201492 sc-201492A | 100 mg 250 mg | $56.00 $100.00 | 9 | |
Has been suggested to impact SPARC expression in certain cancer cell lines, possibly affecting cell-matrix interactions. | ||||||
Emodin | 518-82-1 | sc-202601 sc-202601A sc-202601B | 50 mg 250 mg 15 g | $105.00 $214.00 $6255.00 | 2 | |
Displays anti-cancer potential and might influence SPARC expression as part of its cellular effects. | ||||||
Silybin | 22888-70-6 | sc-202812 sc-202812A sc-202812B sc-202812C | 1 g 5 g 10 g 50 g | $55.00 $114.00 $206.00 $714.00 | 6 | |
Shown to affect SPARC expression in certain cancer cells, potentially influencing cell-matrix interactions and tumor progression. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Although known for other actions, it has been suggested to influence SPARC expression in specific contexts. | ||||||